People | February 20, 2022
Resolution Therapeutics strengthens its team with two new appointments
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
The brand has added a range of exciting new products especially formulated for oily skin.
The agreement also had a permanent safeguard mechanism which can be resorted to in a situation of sudden surge in imports.
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The speakers for the e-conference are: Dr. Mukund Chorgade, President/CSO, THINQ Pharma; Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Jayaseelan J., National Vice President (Industry Division), Indian Pharmaceutical Association; Spandan Mishra who is Director- Sales, Customer Service & Logistics for Evonik India, Nepal & Sri Lanka region; Dr. Kommu Nagaiah, Chief Scientist & Head, CSIR-IICT; Govind K. Jaju, Partner, Suingora Consulting; nd Pravin Prashant, Executive Editor, Indian Pharma Post & Editor, Indian Chemical News.
Funding to grow the insurance and digital therapeutics vertical in India
Subscribe To Our Newsletter & Stay Updated
